Loading
A target and an antibody format: whether the Fc is engineered to recruit killer cells, silenced to avoid them, fused to a trap, or copied as a biosimilar. The corpus holds 149 naked antibodies medicines: 61 approved, 44 in phase 3, 883 trials recruiting, 127 companies named. Every section below says which records it was read from.
From 1 record:Monoclonal antibodies
Lab-made immune proteins that lock onto one target, either blocking it or flagging the cell for destruction.
A humanised or fully human IgG binds a surface or soluble antigen; Fc engineering tunes effector function and half-life.
TermsADCC (antibody-dependent cellular cytotoxicity)Fc engineering / effector functionWhat it costs to aim at a lineage antigenCombined positive score (CPS)Tumour mutational burden (TMB)Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)Immune-related adverse events (irAEs)
From 149 records:AdebrelimabADG126AK117AK119AlemtuzumabALLO-647AtezolizumabAtigotatugand 141 more in the JSON
Target against antibody format, 49 by 6. Open the grid, where every cell links to its medicines and the records behind its state.
From 61 records:RituximabTrastuzumabAlemtuzumabBevacizumabCetuximabHuman normal immunoglobulin (IVIg)PanitumumabBevacizumab (glioblastoma use)and 53 more in the JSON
From 44 records:AK117AtigotatugBCD-100BCD-217BemarituzumabBudigalimabCetrelimabCevostamaband 36 more in the JSON
From 149 records:AdebrelimabADG126AK117AK119AlemtuzumabALLO-647AtezolizumabAtigotatugand 141 more in the JSON
And 39 more, every one a filter pill on the engine table.
From 127 records:Roche / GenentechMerck & Co. (MSD)Bristol Myers SquibbAstraZenecaEli Lilly (incl. Loxo)Shanghai Henlius BiotechBioconJiangsu Hengrui Pharmaceuticalsand 119 more in the JSON
| Company | Type | Medicines | Approved | Phase 3 | Which |
|---|---|---|---|---|---|
| Roche / Genentech CH | pharma | 13 | 8 | 3 | |
| Merck & Co. (MSD) US | pharma | 7 | 2 | 1 | |
| Bristol Myers Squibb US | pharma | 6 | 5 | 1 | |
| AstraZeneca GB | pharma | 6 | 3 | 3 | |
| Eli Lilly (incl. Loxo) US | pharma | 5 | 5 | 0 | |
| Shanghai Henlius Biotech CN | biotech | 5 | 2 | 2 | |
| Biocon IN | pharma | 4 | 4 | 0 | |
| Jiangsu Hengrui Pharmaceuticals CN | pharma | 4 | 3 | 1 | |
| Sanofi FR | pharma | 4 | 3 | 0 | |
| Incyte US | biotech | 4 | 2 | 0 | |
| Pfizer (incl. Seagen) US | pharma | 4 | 1 | 3 | |
| Agenus US | biotech | 4 | 0 | 0 | |
| Biocon Biologics IN | pharma | 3 | 3 | 0 | |
| Halozyme Therapeutics US | biotech | 3 | 3 | 0 | |
| Amgen US | pharma | 3 | 2 | 1 | |
| Johnson & Johnson US | pharma | 3 | 2 | 1 | |
| Regeneron US | pharma | 3 | 2 | 1 | |
| 3SBio CN | biotech | 3 | 1 | 0 | |
| Akeso CN | biotech | 3 | 1 | 1 | |
| GSK GB | pharma | 3 | 1 | 1 |
The 107 others are in the JSON; every medicine's page names its companies.
From 883 records:9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial CancerA Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma PatientsA Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive MutationsA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical CancA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced ColorectalA Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not ReA Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Rand 875 more in the JSON
From 6 records:Immune checkpoint inhibitorsCamrelizumabTislelizumabToripalimabEmapalumabIvermectin
Immune-related adverse events (irAEs) are the autoimmune side effects of checkpoint inhibitors: colitis, thyroid problems, rash, hepatitis, pneumonitis.
Linked fromImmune checkpoint inhibitorsCamrelizumabTislelizumabToripalimab
A flood of inflammatory signals when immune cells are activated en masse, causing fever, low blood pressure, and sometimes organ failure.
Linked fromEmapalumab
Liver injury from a drug, usually detected as a rise in liver enzymes (ALT, AST) on routine blood tests before symptoms appear. Most cases settle with a pause or dose reduction; a few, especially with checkpoint inhibit…
Linked fromIvermectin
From 6 records:PembrolizumabNivolumabAtezolizumabRituximabObinutuzumabGlofitamab
Most patients never respond (primary resistance) and some responders relapse (acquired). The routes are loss of antigen presentation, no T cells in the tumour, and a suppressive microenvironment.
ExemplarsPembrolizumabNivolumabAtezolizumab
B-cell lymphomas escape rituximab either by stopping making CD20, which a report will only show if the relapse is rebiopsied, or by exhausting the complement and effector cells the antibody has to borrow in order to kill.
ExemplarsRituximabObinutuzumabGlofitamab
Hodgkin lymphoma answers PD-1 blockade because it has genetically amplified the brake. When it stops answering, the usual explanation is not the brake but what the Reed-Sternberg cell presents to a T cell.
ExemplarsNivolumabPembrolizumab
From 154 records:Monoclonal antibodiesImmune checkpoint inhibitorsCD47 and SIRP-alpha blockadeCD40 agonist antibodiesAntibody manufacturing (CHO bioprocessing)AdebrelimabADG126AK117and 146 more in the JSON
Cancer therapy using antiparasitic medications guided by acupuncture meridian assessment: a case series of six patients Six patients with advanced cancers treated over a decade with antiparasitic drugs chosen by measuring electrical conductance at acupuncture… | 2,026 | Integrative Medicine (Encinitas) | observational | |
Drug-induced liver injury following co-ingestion of veterinary fenbendazole and ivermectin for prostate cancer: a case report A 65-year-old man with prostate cancer took veterinary fenbendazole and ivermectin on alternate days for three months on the advice of onli… | 2,026 | Cureus | observational | |
Ivermectin toxicity in humans and animals: clinical spectrum, mechanisms, and management A 2026 review of how ivermectin poisons the nervous system: usually safe at approved doses, but encephalopathy, seizures, coma and death ha… | 2,026 | Journal of Applied Toxicology | review | |
Ivermectin-benzimidazole prescribing following celebrity endorsement After a January 2025 podcast promoted ivermectin with a dog dewormer as a cancer cure, US prescriptions of the combination doubled overall… | 2,026 | JAMA Network Open | observational | |
Life-threatening neurotoxicity following off-label ivermectin use in metastatic breast cancer: a case report A 73-year-old woman with metastatic breast cancer took high doses of ivermectin after reading about it online, had seizures and stopped bre… | 2,026 | Postgraduate Medicine | observational | |
Metastatic melanoma with initial ctDNA decline and radiographic response during self-directed antiparasitic use: treatment effect or spontaneous regression? A man with metastatic melanoma who refused standard treatment and took ivermectin and fenbendazole saw his tumour markers and scans improve… | 2,026 | Frontiers in Oncology | observational | |
NCI9673 part B: randomised phase 2 study of nivolumab with or without ipilimumab in refractory metastatic anal cancer Adding ipilimumab to nivolumab for metastatic anal cancer after chemotherapy did not improve response, progression-free survival or overall… | 2,026 | Journal of Clinical Oncology | rct | |
Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in relapsed or refractory diffuse large B-cell lymphoma: results from the phase III, randomized POLARGO trial Adding an antibody-drug conjugate to an outpatient chemotherapy pairing added seven months of median survival for people with relapsed aggr… | 2,026 | Journal of Clinical Oncology | rct | |
Real-world clinical outcomes of ivermectin and mebendazole in cancer patients: results from a prospective observational cohort (with 2026 expression of concern) A telemedicine company's survey of patients it prescribed ivermectin and mebendazole reported that most felt better; the journal has attach… | 2,026 | Anticancer Research | observational | |
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial Adding a third antibody, directed at a different target, to the usual tablet-and-antibody pairing added about eight months before follicula… | 2,026 | Lancet | rct | |
Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma Repeating the SHINE design with a more selective targeted tablet gave another seventeen months before relapse, and again did not extend lif… | 2,025 | Journal of Clinical Oncology | rct | |
AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients In AMPLIFY, an all-oral, 14-month course of acalabrutinib plus venetoclax beat FCR or BR chemo-immunotherapy in fit CLL patients, offering… | 2,025 | New England Journal of Medicine | rct | |
AQUILA: daratumumab versus active monitoring in high-risk smouldering multiple myeloma Giving daratumumab for up to three years to people with high-risk smouldering myeloma roughly halved the risk of progressing to active myel… | 2,025 | New England Journal of Medicine | rct | |
BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer Adding a BRAF inhibitor and an EGFR antibody to first-line chemotherapy roughly doubled survival in BRAF V600E-mutated metastatic bowel can… | 2,025 | New England Journal of Medicine | rct | |
Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma Adding a CD30-directed antibody-drug conjugate to a tablet-and-antibody pairing added about five months of median survival for heavily pret… | 2,025 | Journal of Clinical Oncology | rct | |
C-POST: adjuvant cemiplimab versus placebo in high-risk cutaneous squamous cell carcinoma A year of cemiplimab after surgery and radiotherapy for high-risk cutaneous squamous cell carcinoma cut the risk of recurrence or death by… | 2,025 | New England Journal of Medicine | rct | |
CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint In patients who were transplant-ineligible or deferred transplant, the daratumumab quadruplet raised deep-remission rates from about 39% to… | 2,025 | Nature Medicine | rct | |
CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma Ten years after starting treatment, about half of patients with advanced melanoma treated with nivolumab plus ipilimumab were still alive,… | 2,025 | New England Journal of Medicine | rct | |
CheckMate 8HW: nivolumab plus ipilimumab versus nivolumab alone in MSI-high metastatic colorectal cancer Dual immunotherapy with nivolumab and ipilimumab delayed progression more than nivolumab alone across all lines of treatment in microsatell… | 2,025 | The Lancet | rct | |
DOMAJOR: prolgolimab with chemotherapy first line in advanced non-squamous lung cancer A 292-patient randomised phase 3 in Russia, China, Hungary and Slovakia in which adding the Russian PD-1 antibody prolgolimab to pemetrexed… | 2,025 | European Journal of Cancer | rct | |
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study Three and a half years on, adding durvalumab to chemotherapy for advanced bile duct and gallbladder cancer still showed a survival edge, an… | 2,025 | Journal of Hepatology | rct | |
EMERALD-1: durvalumab with or without bevacizumab added to transarterial chemoembolisation for embolisation-eligible hepatocellular carcinoma Adding durvalumab and bevacizumab to chemoembolisation lengthened the time to progression by about seven months in liver cancer suitable fo… | 2,025 | The Lancet | rct | |
HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer In the first randomised trial to beat pembrolizumab directly, a single antibody that blocks both PD-1 and VEGF nearly doubled the time to p… | 2,025 | The Lancet | rct | |
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial The first trial to show that a chemotherapy-free first-line combination beats immunochemotherapy in older people with mantle cell lymphoma. | 2,025 | Lancet | rct | |
IGNYTE: an engineered herpes virus with nivolumab in melanoma that had already failed anti-PD-1 therapy In melanoma that had already stopped responding to immunotherapy, injecting an engineered herpes virus alongside nivolumab shrank tumours i… | 2,025 | Journal of Clinical Oncology | rct | |
IMvigor011: using a blood test for leftover cancer to decide who gets immunotherapy after bladder surgery Patients whose blood turned positive for tumour DNA after cystectomy lived longer with atezolizumab than placebo; patients who stayed ctDNA… | 2,025 | New England Journal of Medicine | rct | |
Ivermectin and gynecologic cancer: what's the data? Gynaecological oncologists reviewed the evidence for ivermectin in womb, ovarian and cervical cancers, found only cell-line data, and stron… | 2,025 | Gynecologic Oncology Reports | review | |
Ivermectin in cancer treatment: should healthcare providers caution or explore its therapeutic potential? A 2025 review that weighs the laboratory promise against the absence of human trials and concludes that clinicians should counter misinform… | 2,025 | Current Oncology Reports | review | |
Ivermectin treatment for gynecologic cancers: hope versus hype An editorial accompanying the gynaecological review: repurposing is legitimate and early trials deserve support, but no major oncology orga… | 2,025 | Gynecologic Oncology Reports | review | |
KEYNOTE-689: neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck cancer Giving pembrolizumab before surgery and continuing it afterwards alongside radiotherapy reduced recurrences in resectable locally advanced… | 2,025 | New England Journal of Medicine | rct |
From 11 records:Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservationctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatmentDevices and physical therapies roadmap: heat and light → electric fields and focused sound → drug-releasing implantsGallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trialsGlobal access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovationImmunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunityPaediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children firstPancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance questionand 3 more in the JSON
From 154 records:Monoclonal antibodiesImmune checkpoint inhibitorsCD47 and SIRP-alpha blockadeCD40 agonist antibodiesAntibody manufacturing (CHO bioprocessing)AdebrelimabADG126AK117and 146 more in the JSON
A funded programme of organ-preservation trials to avoid radical surgery For some cancers, drugs and radiotherapy can now cure without removing the organ, sparing patients a stoma, a lost voice or a removed bladder. A dedicated prog… | Being tested at scale | |
A public fund for trials that test less treatment No company will pay to find out whether six months of its drug works as well as twelve. A dedicated public fund would pay for those trials, which save patients… | Being tested at scale | |
A risk-stratified cardio-oncology pathway for everyone receiving heart-toxic cancer therapy Some chemotherapy and antibody drugs damage the heart. Checking heart function before and during treatment and starting protective drugs early for those at ris… | Being tested at scale | |
ADC for residual disease after KEYNOTE-522 Patients whose TNBC survives chemo-immunotherapy before surgery have a high relapse risk. Give them an ADC after surgery. | Being tested at scale | |
Approve cancer biosimilars on analytics and pharmacokinetics, no efficacy trials Copies of biological cancer drugs are still required to run large trials that rarely change the answer. Dropping them would cut years and tens of millions from… | Being tested at scale | |
Automatic price cuts when a cancer drug's approved indications and volumes expand When a cancer drug is approved for more uses, the company sells far more of it but the price stays the same. Japan cuts prices automatically when sales balloon… | Being tested at scale | |
Biosimilar-first defaults and payment parity in every cancer day unit Cheaper copies of biological cancer drugs exist but are used far less in some countries than others. Making them the default choice saves billions with no loss… | Being tested at scale | |
Chemotherapy before the second operation for high-risk incidental gallbladder cancer Gallbladder cancers found by chance often come back within six months of the second operation, usually far from the gallbladder, which suggests the disease was… | Being tested at scale | |
Fixed-duration, chemotherapy-free first-line treatment for the indolent lymphomas Several treatments now work without chemotherapy, but most are given until the disease comes back. Giving them for a fixed time and stopping is the version pat… | Being tested at scale | |
Give exceptional responders less: pembrolizumab omission after complete response, anthracycline-free regimens and chemotherapy omission in lymphocyte-rich stage I disease Two thirds of women treated on the KEYNOTE-522 regimen have no tumour left at surgery and about 92 percent of them are alive without relapse at five years, yet… | Being tested at scale | |
Home administration of selected chemotherapy and immunotherapy for older and frail patients For frail older patients, the journey to hospital can be the hardest part of treatment. Nurses can safely give some cancer treatments at home, which may help m… | Being tested at scale | |
Make six-weekly immunotherapy the default schedule Pembrolizumab 400 mg every six weeks is approved and works like 200 mg every three weeks, and it halves the number of clinic visits, infusion chairs and travel… | Being tested at scale | |
Make the biosimilar the default at the pharmacy for trastuzumab, bevacizumab and rituximab Copies of the big antibody drugs are approved and cheaper, but uptake depends on each prescriber; letting the pharmacy substitute the biosimilar unless the onc… | Being tested at scale | |
Molecular-class-directed adjuvant therapy in endometrial cancer Give adjuvant treatment by the tumour's molecular class rather than by stage and grade: nothing for POLE-mutated, immunotherapy for MMRd, chemotherapy plus tar… | Being tested at scale | |
MRD-guided treatment-free intervals in myeloma If a patient has had no detectable myeloma for a year or more, stop maintenance and watch, restarting only if disease reappears. | Being tested at scale | |
Organ preservation as the default after complete response in oesophageal cancer Oesophagectomy is one of the hardest operations in surgery. If chemoradiation (with or without immunotherapy) has made the tumour disappear, skip it and watch. | Being tested at scale | |
Pooled international procurement of essential adult cancer medicines Countries buying cancer drugs alone pay more and face shortages. Buying together, as they already do for childhood cancer drugs and vaccines, cuts prices and s… | Being tested at scale | |
Publicly funded dose-reduction trials of expensive approved drugs Some expensive approved cancer drugs probably work as well at lower doses, as reduced-dose abiraterone with food and extended-interval checkpoint inhibitors su… | Being tested at scale | |
Publicly funded trials of lower and less frequent doses of expensive cancer drugs Abiraterone at a quarter dose with food matches full-dose exposure, and pembrolizumab and nivolumab can be given at longer intervals, but no manufacturer will… | Being tested at scale | |
Randomise organ preservation against surgery in mismatch repair-proficient rectal cancer, with bowel function as a co-primary endpoint Half of rectal cancer patients given all their chemotherapy and radiotherapy first can keep their rectum. Nobody has ever randomised that against having the op… | Being tested at scale | |
Randomised trials of stopping immunotherapy after one year versus continuing Immunotherapy is often given for two years or until it stops working, but responses can last long after stopping. Trials that randomly assign responders to sto… | Being tested at scale | |
Use pre-surgery immunotherapy windows as the field's biomarker engine Giving immunotherapy for a few weeks before surgery produces a tumour sample that shows exactly what the drug did. That is the fastest way to learn who respond… | Being tested at scale | |
A ctDNA residual disease-guided adjuvant trial after gallbladder cancer resection After surgery for bile duct or gallbladder cancer, a blood test for leftover tumour DNA picks out the people whose cancer will return with hazard ratios of 16… | Early clinical | |
A national late-effects registry linking treatment exposures to outcomes decades later We know surprisingly little about what happens to cancer survivors twenty years on. Linking their treatment records to later health records would show which tr… | Early clinical | |
A neutral platform trial for radiotherapy plus immunotherapy combinations Radiotherapy may make immunotherapy work better, but the trials to test this are scattered and often small. One shared platform, run by radiotherapy groups wit… | Early clinical | |
A single calibrated tumour mutational burden across all sequencing panels Tumour mutational burden decides who gets immunotherapy in some settings, but every sequencing panel calculates it differently. A shared calibration would make… | Early clinical | |
Antibody-drug conjugates for mesothelioma: why they have failed so far and how they could work Nearly every mesothelioma carries the surface protein mesothelin, yet the one antibody-drug conjugate tried in a randomised trial did no better than chemothera… | Early clinical | |
Biomarker-directed first-line quadruplets in gastric cancer Stomach cancer now has three add-on biomarkers (HER2, PD-L1, Claudin 18.2) that often overlap. Test whether combining two add-ons beats picking one. | Early clinical | |
Biomarker-guided cardioprotection for everyone on cardiotoxic cancer therapy Anthracyclines, HER2 drugs and some newer agents can damage the heart. Monitor with blood tests and scans and start cheap heart-protective drugs early in those… | Early clinical | |
Biomarker-selected adjuvant therapy in RCC (ctDNA, CAIX PET, gene signatures) Adjuvant immunotherapy after kidney cancer surgery is given to everyone at high pathological risk although most would never relapse, so a year of toxicity is s… | Early clinical |
From 1 record:Antibody manufacturing (CHO bioprocessing)
CHO cell culture, Protein A purification, single-use plants and fill-finish, and the biosimilar copies that cut prices.
Antibody manufacturing (CHO bioprocessing)Downstream purification (Protein A capture, viral clearance, polishing)Single-use bioprocessing systemsSterile fill-finish and lyophilisationBiosimilar manufacturing and comparability
CompaniesSamsung BiologicsLonzaWuXi BiologicsFUJIFILM Diosynth BiotechnologiesBoehringer Ingelheim BioXcellenceThermo Fisher ScientificCatalent (Novo Holdings)Cytiva (Danaher)SartoriusMerck KGaA (EMD Serono)CelltrionSamsung BioepisBioconAmgen
| Site | Operator | Capabilities | Makes | Source |
|---|---|---|---|---|
| Abzena Sanford Sanford, North Carolina, US · contract manufacturer | Abzena | ADC conjugationAntibody drug substance | Abzena | |
| Bristol Myers Squibb Devens Devens, Massachusetts, US · in-house | Bristol Myers Squibb | Cell therapyAntibody drug substance | BMS manufacturing | |
| Catalent Bloomington Bloomington, Indiana, US · contract manufacturer | Catalent (Novo Holdings) | Antibody drug substanceFill and finish | Catalent Biologics | |
| FUJIFILM Diosynth Holly Springs Holly Springs, North Carolina, US · contract manufacturer | FUJIFILM Diosynth Biotechnologies | Antibody drug substanceFill and finish | FUJIFILM Diosynth Biotechnologies | |
| Lonza Visp Visp, CH · contract manufacturer | Lonza | ADC conjugationPayload and linker chemistryAntibody drug substance | Lonza bioconjugates | |
| Samsung Biologics ADC facility Incheon (Songdo), KR · contract manufacturer | Samsung Biologics | ADC conjugationAntibody drug substance | Samsung Biologics | |
| WuXi XDC Wuxi Wuxi, CN · contract manufacturer | WuXi XDC | ADC conjugationPayload and linker chemistryAntibody drug substanceFill and finish | WuXi XDC |
The manufacturing map draws every site and the seven supply chains.
Antibody manufacturing means growing antibody drugs like pembrolizumab or trastuzumab in vats of engineered hamster cells, then purifying them. It is the industrial base for most modern cancer drugs.
The medicines are the ones the open drug engine files under naked antibodies, whether it placed them on its grid or listed them as unresolved. The technology records are listed by hand (src/lib/modular-formats.ts) and each carries a pill back here. Everything else follows the graph's links from those two sets: approvals, cancers and toxicity from the medicine records; companies, trials, papers and ideas from the records that name a medicine or technology; roadmap steps from their refs; resistance from the atlas; manufacturing from the site and supply chain records.
Nothing here is written for the hub. Where the corpus holds no record for a section, the section says so rather than filling the gap, and the counts are counts of records in OnCo, not of the world. The JSON companion carries every section with the record ids behind it. Not medical advice.